Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Bruce Baguley

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

Anatomy

Cultured Tumor Cells

Disorders

Concepts & Ideas

Procedures

Neoplasm Transplantation

Physiology

Cell Survival

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
56
Ching, Lai-Ming
40
Finlay, Graeme
35
Kestell, Philip
21
Wilson, William
20
Marshall, Elaine
19
Joseph, Wayne
19
Paxton, James
19
Atwell, Graham
18
Rewcastle, Gordon
17
Palmer, Brian
14
Denny, William
14
Ferguson, Lynnette
11
McKeage, Mark
11
Zhuang, L
9
Zhao, Liangli

Sign-in to see all Coauthors

Publications

TOP 3
Ramachandran Anassuya; Marshall Elaine S; Love Donald R; Baguley Bruce C; Shelling Andrew N
Activin is a potent growth suppressor of epithelial ovarian cancer cells.
Daukste Liene; Basse Britta; Baguley Bruce C; Wall David J N
Using a stem cell and progeny model to illustrate the relationship between cell cycle times of in vivo human tumour cell tissue populations, in vitro primary cultures and the cell lines derived from them.
Wang L-C Steve; Ching Lai-Ming; Paxton James W; Kestell Philip; Sutherland Rachel; Zhuang Li; Baguley Bruce C
Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Bruce Baguley (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Ramachandran Anassuya; Marshall Elaine S; Love Donald R; Baguley Bruce C; Shelling Andrew N
Activin is a potent growth suppressor of epithelial ovarian cancer cells.
Cancer letters 2009;285(2):157-65.
2009: Daukste Liene; Basse Britta; Baguley Bruce C; Wall David J N
Using a stem cell and progeny model to illustrate the relationship between cell cycle times of in vivo human tumour cell tissue populations, in vitro primary cultures and the cell lines derived from them.
Journal of theoretical biology 2009;260(4):563-71.
2009: Wang L-C Steve; Ching Lai-Ming; Paxton James W; Kestell Philip; Sutherland Rachel; Zhuang Li; Baguley Bruce C
Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs.
Investigational new drugs 2009;27(3):280-4.
2009: Ganta Srinivas; Paxton James W; Baguley Bruce C; Garg Sanjay
Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery.
International journal of pharmaceutics 2009;367(1-2):179-86.
2008: Lukka Pradeep B; Kestell Philip; Paxton James W; Baguley Bruce C
Development and validation of a liquid chromatography-mass spectrometry (LC-MS) assay for the determination of the anti-cancer agent N-[2-(dimethylamino)ethyl]-2,6-dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-4-carboxamide (SN 28049).
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;875(2):368-72.
2008: Bridewell David J A; Porter Andrew C G; Finlay Graeme J; Baguley Bruce C
The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049.
Cancer chemotherapy and pharmacology 2008;62(5):753-62.
2008: Ganta Srinivas; Paxton James W; Baguley Bruce C; Garg Sanjay
Pharmacokinetics and pharmacodynamics of chlorambucil delivered in parenteral emulsion.
International journal of pharmaceutics 2008;360(1-2):115-21.
2008: Li Jing; Jameson Michael B; Baguley Bruce C; Pili Roberto; Baker Sharyn D
Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(7):2102-10.
2008: Chung Francisco; Liu Jenny; Ching Lai-Ming; Baguley Bruce C
Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide.
Cancer chemotherapy and pharmacology 2008;61(3):497-502.
2008: Liu Johnson J; Galettis Peter; Farr Alistair; Maharaj Lenushka; Samarasinha Hasitha; McGechan Adam C; Baguley Bruce C; Bowen Richard J; Berners-Price Susan J; McKeage Mark J
In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake.
Journal of inorganic biochemistry 2008;102(2):303-10.
2008: Ganta Srinivas; Paxton James W; Baguley Bruce C; Garg Sanjay
Development and validation of bioanalytical method for the determination of asulacrine in plasma by liquid chromatography.
Journal of pharmaceutical and biomedical analysis 2008;46(2):386-90.
2007: Kendall Jackie D; Rewcastle Gordon W; Frederick Raphael; Mawson Claire; Denny William A; Marshall Elaine S; Baguley Bruce C; Chaussade Claire; Jackson Shaun P; Shepherd Peter R
Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110alpha inhibitors.
Bioorganic & medicinal chemistry 2007;15(24):7677-87.
2007: Zhao Liangli; Marshall Elaine S; Kelland Lloyd R; Baguley Bruce C
Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Investigational new drugs 2007;25(3):271-6.
2007: Jameson M B; Baguley B C; Kestell P; Zhao L; Paxton J W; Thompson P I; Waller S;
Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial.
Cancer chemotherapy and pharmacology 2007;59(5):681-7.
2007: Liu Johnson J; Ching Lai-Ming; Goldthorpe Michael; Sutherland Rachel; Baguley Bruce C; Kirker James A; McKeage Mark J
Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours.
Cancer chemotherapy and pharmacology 2007;59(5):661-9.
2007: Woon See-Tarn; Hung Sandy S C; Wu Derek C F; Schooltink Mary Ann; Sutherland Rachel; Baguley Bruce C; Chen Qi; Chamley Lawrence W; Ching Lai-Ming
NF-kappaB-independent induction of endothelial cell apoptosis by the vascular disrupting agent DMXAA.
Anticancer research 2007;27(1A):327-34.
2006: McKeage Mark J; Fong Peter; Jeffery Mark; Baguley Bruce C; Kestell Phil; Ravic Miroslav; Jameson Michael B
5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(6):1776-84.
2006: Gamage Swarna A; Rewcastle Gordon W; Baguley Bruce C; Charlton Peter A; Denny William A
Phenazine-1-carboxamides: structure-cytotoxicity relationships for 9-substituents and changes in the H-bonding pattern of the cationic side chain.
Bioorganic & medicinal chemistry 2006;14(4):1160-8.
2006: Baguley Bruce C
Tumor stem cell niches: a new functional framework for the action of anticancer drugs.
Recent patents on anti-cancer drug discovery 2006;1(1):121-7.
2006: Wang Liang-Chuan S; Woon See-Tarn; Baguley Bruce C; Ching Lai-Ming
Inhibition of DMXAA-induced tumor necrosis factor production in murine splenocyte cultures by NF-kappaB inhibitors.
Oncology research 2006;16(1):1-14.
2005: Zhao Liangli; Ching Lai-Ming; Kestell Philip; Kelland Lloyd R; Baguley Bruce C
Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability.
International journal of cancer. Journal international du cancer 2005;116(2):322-6.
2005: Basse Britta; Baguley Bruce C; Marshall Elaine S; Wake Graeme C; Wall David J N
Modelling the flow [corrected] cytometric data obtained from unperturbed human tumour cell lines: parameter fitting and comparison.
Bulletin of mathematical biology 2005;67(4):815-30.
2005: Woon See-Tarn; Reddy Charu B; Drummond Catherine J; Schooltink Mary Ann; Baguley Bruce C; Kieda Claudine; Ching Lai-Ming
A comparison of the ability of DMXAA and xanthenone analogues to activate NF-kappaB in murine and human cell lines.
Oncology research 2005;15(7-8):351-64.
2005: Baguley Bruce C; Marshall Elaine
Do negative feedback oscillations drive variations in the length of the tumor cell division cycle?
Oncology research 2005;15(6):291-4.
2004: Basse Britta; Baguley Bruce C; Marshall Elaine S; Joseph Wayne R; van Brunt Bruce; Wake Graeme; Wall David J N
Modelling cell death in human tumour cell lines exposed to the anticancer drug paclitaxel.
Journal of mathematical biology 2004;49(4):329-57.
2004: Chung Francisco; Lu Jun; Palmer Brian D; Kestell Philip; Browett Peter; Baguley Bruce C; Tingle Malcolm; Ching Lai-Ming
Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(17):5949-56.
2004: Zhou Shufeng; Feng Xia; Kestell Philip; Baguley Bruce C; Paxton James W
Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;809(1):87-97.
2004: Lu Jun; Helsby Nuala; Palmer Brian D; Tingle Malcolm; Baguley Bruce C; Kestell Philip; Ching Lai-Ming
Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans.
The Journal of pharmacology and experimental therapeutics 2004;310(2):571-7.
2004: Basse Britta; Baguley Bruce C; Marshall Elaine S; Wake Graeme C; Wall David J N
Modelling cell population growth with applications to cancer therapy in human tumour cell lines.
Progress in biophysics and molecular biology 2004;85(2-3):353-68.
2004: Chung Francisco; Wang Liang-Chuan S; Kestell Philip; Baguley Bruce C; Ching Lai-Ming
Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor.
Cancer chemotherapy and pharmacology 2004;53(5):377-83.
2004: Baguley B C; Marshall E S
In vitro modelling of human tumour behaviour in drug discovery programmes.
European journal of cancer (Oxford, England : 1990) 2004;40(6):794-801.
2004: Wang Liang-Chuan S; Reddy Charu B; Baguley Bruce C; Kestell Philip; Sutherland Rachel; Ching Lai-Ming
Induction of tumour necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites.
Biochemical pharmacology 2004;67(5):937-45.
2004: Ching L-M; Zwain S; Baguley B C
Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice.
British journal of cancer 2004;90(4):906-10.
2004: Marshall Elaine S; Baguley Bruce C; Matthews John H L; Jose Chakiath C; Furneaux Christopher E; Shaw James H F; Kirker James A; Morton Randall P; White Julian B; Rice Michael L; Isaacs Richard J; Coutts Richard; Whittaker John R
Estimation of radiation-induced interphase cell death in cultures of human tumor material and in cell lines.
Oncology research 2004;14(6):297-304.
2003: Zhao Liangli; Ching Lai-Ming; Kestell Philip; Baguley Bruce C
Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(17):6545-50.
2003: Baguley Bruce C; Wakelin Laurence P G; Jacintho Jason D; Kovacic Peter
Mechanisms of action of DNA intercalating acridine-based drugs: how important are contributions from electron transfer and oxidative stress?
Current medicinal chemistry 2003;10(24):2643-9.
2003: Basse Britta; Baguley Bruce C; Marshall Elaine S; Joseph Wayne R; van Brunt Bruce; Wake Graeme; Wall David J N
A mathematical model for analysis of the cell cycle in cell lines derived from human tumors.
Journal of mathematical biology 2003;47(4):295-312.
2003: Jamieson S M F; Liu J; Hsu T; Baguley B C; McKeage M J
Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity.
British journal of cancer 2003;88(12):1942-7.
2003: Jameson M B; Thompson P I; Baguley B C; Evans B D; Harvey V J; Porter D J; McCrystal M R; Small M; Bellenger K; Gumbrell L; Halbert G W; Kestell P;
Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent.
British journal of cancer 2003;88(12):1844-50.
2003: Zhou Shufeng; Kestell Philip; Baguley Bruce C; Paxton James W
Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
Biochemical pharmacology 2003;65(11):1853-65.
2003: Lu Jun; Palmer Brian D; Kestell Phillip; Browett Peter; Baguley Bruce C; Muller George; Ching Lai-Ming
Thalidomide metabolites in mice and patients with multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(5):1680-8.
2003: Woon S-T; Zwain S; Schooltink M A; Newth A L; Baguley B C; Ching L-M
NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
European journal of cancer (Oxford, England : 1990) 2003;39(8):1176-83.
2003: Baguley Bruce C
Antivascular therapy of cancer: DMXAA.
The lancet oncology 2003;4(3):141-8.
2003: Zhou Shufeng; Kestell Philip; Baguley Bruce C; Paxton James W
Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
Biochemical pharmacology 2003;65(1):109-20.
2003: Chung Francisco; Palmer Brian D; Muller George W; Man Hon-Wah; Kestell Phillip; Baguley Bruce C; Ching Lai-Ming
Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Oncology research 2003;14(2):75-82.
2003: Denny William A; Baguley Bruce C
Dual topoisomerase I/II inhibitors in cancer therapy.
Current topics in medicinal chemistry 2003;3(3):339-53.
2003: Baguley Bruce C; Marshall Elaine S; Christmas Timothy I
Cultures of surgical material from lung cancers. A kinetic approach.
Methods in molecular medicine 2003;74():527-44.
2002: Baguley Bruce C; Ching Lai Ming
DMXAA: an antivascular agent with multiple host responses.
International journal of radiation oncology, biology, physics 2002;54(5):1503-11.
2002: Baguley Bruce C; Wilson William R
Potential of DMXAA combination therapy for solid tumors.
Expert review of anticancer therapy 2002;2(5):593-603.
2002: Ding Qi; Kestell Philip; Baguley Bruce C; Palmer Brian D; Paxton James W; Muller George; Ching Lai-Ming
Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide.
Cancer chemotherapy and pharmacology 2002;50(3):186-92.
2002: Zhou Shufeng; Kestell Philip; Baguley Bruce C; Paxton James W
5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
Investigational new drugs 2002;20(3):281-95.
2002: Zhao L; Ching L-M; Kestell P; Baguley B C
The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice.
British journal of cancer 2002;87(4):465-70.
2002: Ching L-M; Cao Z; Kieda C; Zwain S; Jameson M B; Baguley B C
Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid.
British journal of cancer 2002;86(12):1937-42.
2002: Mistry Prakash; Stewart Alistair J; Dangerfield Wendy; Baker Mark; Liddle Chris; Bootle Douglas; Kofler Bettina; Laurie Deanne; Denny William A; Baguley Bruce; Charlton Peter A
In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II.
Anti-cancer drugs 2002;13(1):15-28.
2002: Zhao Liangli; Kestell Philip; Ching Lai-Ming; Baguley Bruce C
Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.
Cancer chemotherapy and pharmacology 2002;49(1):20-6.
2002: Woon See-Tarn; Baguley Bruce C; Palmer Brian D; Fraser John D; Ching Lai-Ming
Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappaB in human tumor cell lines.
Oncology research 2002;13(2):95-101.
2002: Baguley Bruce C
Novel strategies for overcoming multidrug resistance in cancer.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2002;16(2):97-103.
2001: Bridewell D J; Finlay G J; Baguley B C
Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
Anti-cancer drug design 2001;16(6):317-24.
2001: Kestell P; Zhao L; Jameson M B; Stratford M R; Folkes L K; Baguley B C
Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents.
Clinica chimica acta; international journal of clinical chemistry 2001;314(1-2):159-66.
2001: McKeage M J; Hsu T; Screnci D; Haddad G; Baguley B C
Nucleolar damage correlates with neurotoxicity induced by different platinum drugs.
British journal of cancer 2001;85(8):1219-25.
2001: Philpott M; Ching L M; Baguley B C
The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor.
European journal of cancer (Oxford, England : 1990) 2001;37(15):1930-7.
2001: Baguley B C
Small-molecule cytokine inducers causing tumor necrosis.
Current opinion in investigational drugs (London, England : 2000) 2001;2(7):967-75.
2001: Zhao L; Kestell P; Philpott M; Ching L M; Zhuang L; Baguley B C
Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Cancer chemotherapy and pharmacology 2001;47(6):491-7.
2001: Hicks K O; Pruijn F B; Baguley B C; Wilson W R
Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (DACA): diffusion and metabolism in multicellular layers of tumor cells.
The Journal of pharmacology and experimental therapeutics 2001;297(3):1088-98.
2001: Zhou S F; Paxton J W; Tingle M D; Kestell P; Jameson M B; Thompson P I; Baguley B C
Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans.
Xenobiotica; the fate of foreign compounds in biological systems 2001;31(5):277-93.
2001: Stewart A J; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley B C; Denny W A; Charlton P A
Antitumor activity of XR5944, a novel and potent topoisomerase poison.
Anti-cancer drugs 2001;12(4):359-67.
2001: Gamage S A; Spicer J A; Finlay G J; Stewart A J; Charlton P; Baguley B C; Denny W A
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
Journal of medicinal chemistry 2001;44(9):1407-15.
2001: Cao Z; Baguley B C; Ching L M
Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Cancer research 2001;61(4):1517-21.
2000: Spicer J A; Gamage S A; Rewcastle G W; Finlay G J; Bridewell D J; Baguley B C; Denny W A
Bis(phenazine-1-carboxamides): structure-activity relationships for a new class of dual topoisomerase I/II-directed anticancer drugs.
Journal of medicinal chemistry 2000;43(7):1350-8.
2000: Screnci D; McKeage M J; Galettis P; Hambley T W; Palmer B D; Baguley B C
Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs.
British journal of cancer 2000;82(4):966-72.
2000: Parmar J; Marshall E S; Charters G A; Holdaway K M; Shelling A N; Baguley B C
Radiation-induced cell cycle delays and p53 status of early passage melanoma cell lines.
Oncology research 2000;12(3):149-55.
2000: McKeage M J; Berners-Price S J; Galettis P; Bowen R J; Brouwer W; Ding L; Zhuang L; Baguley B C
Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes.
Cancer chemotherapy and pharmacology 2000;46(5):343-50.
2000: Kestell P; Zhao L; Baguley B C; Palmer B D; Muller G; Paxton J W; Ching L M
Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide.
Cancer chemotherapy and pharmacology 2000;46(2):135-41.
2000: Finlay G J; Baguley B C
Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs.
Cancer chemotherapy and pharmacology 2000;45(5):417-22.
1999: Ching L M; Goldsmith D; Joseph W R; Körner H; Sedgwick J D; Baguley B C
Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice.
Cancer research 1999;59(14):3304-7.
1999: Gamage S A; Spicer J A; Atwell G J; Finlay G J; Baguley B C; Denny W A
Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
Journal of medicinal chemistry 1999;42(13):2383-93.
1999: Spicer J A; Gamage S A; Atwell G J; Finlay G J; Baguley B C; Denny W A
Dimeric analogues of non-cationic tricyclic aromatic carboxamides are a new class of cytotoxic agents.
Anti-cancer drug design 1999;14(3):281-9.
1999: Haldane A; Finlay G J; Hay M P; Denny W A; Baguley B C
Cellular uptake of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
Anti-cancer drug design 1999;14(3):275-80.
1999: Cao Z; Joseph W R; Browne W L; Mountjoy K G; Palmer B D; Baguley B C; Ching L M
Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
British journal of cancer 1999;80(5-6):716-23.
1999: Spicer J A; Finlay G J; Baguley B C; Velea L; Graves D E; Denny W A
5,7-Disubstituted analogues of the mixed topoisomerase I/II poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA): DNA binding and patterns of cytotoxicity.
Anti-cancer drug design 1999;14(1):37-45.
1999: Joseph W R; Cao Z; Mountjoy K G; Marshall E S; Baguley B C; Ching L M
Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.
Cancer research 1999;59(3):633-8.
1999: McKeage M J; Haddad G G; Ding L; Galettis P; Screnci D; Zhuang L; Baguley B C
Neuroprotective interactions in rats between paclitaxel and cisplatin.
Oncology research 1999;11(6):287-93.
1999: Finlay G J; Atwell G J; Baguley B C
Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
Oncology research 1999;11(6):249-54.
1999: Baguley B C; Marshall E S; Finlay G J
Short-term cultures of clinical tumor material: potential contributions to oncology research.
Oncology research 1999;11(3):115-24.
1999: Schofield P C; Robertson I G; Paxton J W; McCrystal M R; Evans B D; Kestell P; Baguley B C
Metabolism of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in cancer patients undergoing a phase I clinical trial.
Cancer chemotherapy and pharmacology 1999;44(1):51-8.
1999: Kestell P; Dunlop I C; McCrystal M R; Evans B D; Paxton J W; Gamage R S; Baguley B C
Plasma pharmacokinetics of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial.
Cancer chemotherapy and pharmacology 1999;44(1):45-50.
1999: McCrystal M R; Evans B D; Harvey V J; Thompson P I; Porter D J; Baguley B C
Phase I study of the cytotoxic agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
Cancer chemotherapy and pharmacology 1999;44(1):39-44.
1999: Kestell P; Paxton J W; Rewcastle G W; Dunlop I; Baguley B C
Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit.
Cancer chemotherapy and pharmacology 1999;43(4):323-30.
1999: Bridewell D J; Finlay G J; Baguley B C
Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
Cancer chemotherapy and pharmacology 1999;43(4):302-8.
1998: Browne W L; Wilson W R; Baguley B C; Ching L M
Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid.
Anticancer research 1998;18(6A):4409-13.
1998: Baguley B C; Ferguson L R
Mutagenic properties of topoisomerase-targeted drugs.
Biochimica et biophysica acta 1998;1400(1-3):213-22.
1998: Lash C J; Li A E; Rutland M; Baguley B C; Zwi L J; Wilson W R
Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
British journal of cancer 1998;78(4):439-45.
1998: Ching L M; Browne W L; Tchernegovski R; Gregory T; Baguley B C; Palmer B D
Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.
British journal of cancer 1998;78(3):336-43.
1998: Pang J H; Cao Z; Joseph W R; Baguley B C; Ching L M
Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptor.
European journal of cancer (Oxford, England : 1990) 1998;34(8):1282-9.
1998: Baguley B C; Marshall E S; Holdaway K M; Rewcastle G W; Denny W A
Inhibition of growth of primary human tumour cell cultures by a 4-anilinoquinazoline inhibitor of the epidermal growth factor receptor family of tyrosine kinases.
European journal of cancer (Oxford, England : 1990) 1998;34(7):1086-90.
1997: Moreland N; Finlay G J; Dragunow M; Holdaway K M; Baguley B C
Cellular responses to methyl-N-[4-9-acridinylamino)-2-methoxyphenyl] carbamate hydrochloride, an analogue of amsacrine active against non-proliferating cells.
European journal of cancer (Oxford, England : 1990) 1997;33(10):1668-76.
1997: Baguley B C; Ching L M
Immunomodulatory actions of xanthenone anticancer agents.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 1997;8(2):119-27.
1997: Spicer J A; Gamage S A; Atwell G J; Finlay G J; Baguley B C; Denny W A
Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
Journal of medicinal chemistry 1997;40(12):1919-29.
1997: Fan J Y; Valu K K; Woodgate P D; Baguley B C; Denny W A
Aniline mustard analogues of the DNA-intercalating agent amsacrine: DNA interaction and biological activity.
Anti-cancer drug design 1997;12(3):181-203.
1997: Baguley B C; Leteurtre F; Riou J F; Finlay G J; Pommier Y
A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine.
European journal of cancer (Oxford, England : 1990) 1997;33(2):272-9.
1997: Bridewell D J; Finlay G J; Baguley B C
Differential actions of aclarubicin and doxorubicin: the role of topoisomerase I.
Oncology research 1997;9(10):535-42.
1997: Philpott M; Joseph W R; Crosier K E; Baguley B C; Ching L M
Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).
British journal of cancer 1997;76(12):1586-91.
1997: Baguley B C; Zhuang L; Kestell P
Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects.
Oncology research 1997;9(2):55-60.
1996: Ferguson L R; Baguley B C
Mutagenicity of anticancer drugs that inhibit topoisomerase enzymes.
Mutation research 1996;355(1-2):91-101.
1996: Finlay G J; Riou J F; Baguley B C
From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives.
European journal of cancer (Oxford, England : 1990) 1996;32A(4):708-14.
1996: Ferguson L R; Whiteside G; Holdaway K M; Baguley B C
Application of fluorescence in situ hybridisation to study the relationship between cytotoxicity, chromosome aberrations, and changes in chromosome number after treatment with the topoisomerase II inhibitor amsacrine.
Environmental and molecular mutagenesis 1996;27(4):255-62.
1995: Baguley B C; Finlay G J
Pharmacokinetic/cytokinetic principles in the chemotherapy of solid tumours.
Clinical and experimental pharmacology & physiology 1995;22(11):825-8.
1995: Ching L M; Xu Z F; Gummer B H; Palmer B D; Joseph W R; Baguley B C
Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid.
British journal of cancer 1995;72(2):339-43.
1995: Atwell G J; Yaghi B M; Turner P R; Boyd M; O'Connor C J; Ferguson L R; Baguley B C; Denny W A
Synthesis, DNA interactions and biological activity of DNA minor groove targeted polybenzamide-linked nitrogen mustards.
Bioorganic & medicinal chemistry 1995;3(6):679-91.
1995: Baguley B C; Zhuang L; Marshall E
Experimental solid tumour activity of N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide.
Cancer chemotherapy and pharmacology 1995;36(3):244-8.
1995: Philpott M; Baguley B C; Ching L M
Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid.
Cancer chemotherapy and pharmacology 1995;36(2):143-8.
1995: Baguley B C; Marshall E S; Whittaker J R; Dotchin M C; Nixon J; McCrystal M R; Finlay G J; Matthews J H; Holdaway K M; van Zijl P
Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer.
European journal of cancer (Oxford, England : 1990) 1995;31A(2):230-7.
1995: Veszelovsky E; Holford N H; Thomsen L L; Knowles R G; Baguley B C
Plasma nitrate clearance in mice: modeling of the systemic production of nitrate following the induction of nitric oxide synthesis.
Cancer chemotherapy and pharmacology 1995;36(2):155-9.
1994: Gravatt G L; Baguley B C; Wilson W R; Denny W A
DNA-directed alkylating agents. 6. Synthesis and antitumor activity of DNA minor groove-targeted aniline mustard analogues of pibenzimol (Hoechst 33258)
Journal of medicinal chemistry 1994;37(25):4338-45.
1994: Kestell P; Rewcastle G W; Baguley B C
Disposition of the novel antitumour agent xanthenone-4-acetic acid in the mouse: identification of metabolites and routes of elimination.
Xenobiotica; the fate of foreign compounds in biological systems 1994;24(7):635-47.
1994: Cliffe S; Taylor M L; Rutland M; Baguley B C; Hill R P; Wilson W R
Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid.
International journal of radiation oncology, biology, physics 1994;29(2):373-7.
1994: Zwi L J; Baguley B C; Gavin J B; Wilson W R
The morphological effects of the anti-tumor agents flavone acetic acid and 5,6-dimethyl xanthenone acetic acid on the colon 38 mouse tumor.
Pathology 1994;26(2):161-9.
1994: Ching L M; Joseph W R; Crosier K E; Baguley B C
Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).
Cancer research 1994;54(4):870-2.
1994: Finlay G J; Holdaway K M; Baguley B C
Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells.
Cancer chemotherapy and pharmacology 1994;34(2):159-65.
1994: Marshall E S; Matthews J H; Shaw J H; Nixon J; Tumewu P; Finlay G J; Holdaway K M; Baguley B C
Radiosensitivity of new and established human melanoma cell lines: comparison of [3H]thymidine incorporation and soft agar clonogenic assays.
European journal of cancer (Oxford, England : 1990) 1994;30A(9):1370-6.
1994: Ching L M; Joseph W R; Zhuang L; Baguley B C
Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours.
Cancer chemotherapy and pharmacology 1994;35(2):153-60.
1994: Zwi L J; Baguley B C; Gavin J B; Wilson W R
Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents.
Oncology research 1994;6(2):79-85.
1994: Finlay G J; Holdaway K M; Baguley B C
Comparison of the effects of genistein and amsacrine on leukemia cell proliferation.
Oncology research 1994;6(1):33-7.
1994: Ferguson L R; Baguley B C
Topoisomerase II enzymes and mutagenicity.
Environmental and molecular mutagenesis 1994;24(4):245-61.
1993: Ching L M; Joseph W R; Baguley B C
Effect of tumour growth on the macrophage response to the antitumour agent 5,6-dimethylxanthenone-4-acetic acid.
Anticancer research 1993;13(6A):2069-75.
1993: Ferguson L R; Turner P M; Baguley B C
Induction of mitotic crossing-over by the topoisomerase II poison DACA (N-[2-dimethylamino)ethyl]acridine-4-carboxamide) in Saccharomyces cerevisiae.
Mutation research 1993;289(2):157-63.
1993: Ching L M; Joseph W R; Baguley B C
Inhibition of antitumor effects of flavone acetic acid by cortisone.
Anticancer research 1993;13(4):1139-41.
1993: Ferguson L R; Baguley B C
Multidrug resistance and mutagenesis.
Mutation research 1993;285(1):79-90.
1993: Veszelovszky E; Thomsen L L; Li Z; Baguley B C
Flavone acetic acid and 5,6-dimethylxanthenone-4-acetic acid: relationship between plasma nitrate elevation and the induction of tumour necrosis.
European journal of cancer (Oxford, England : 1990) 1993;29A(3):404-8.
1993: Finlay G J; Marshall E; Matthews J H; Paull K D; Baguley B C
In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance.
Cancer chemotherapy and pharmacology 1993;31(5):401-6.
1993: Baguley B C; Cole G; Thomsen L L; Li Z
Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid.
Cancer chemotherapy and pharmacology 1993;33(1):77-81.
1993: Haldane A; Finlay G J; Baguley B C
A comparison of the effects of aphidicolin and other inhibitors on topoisomerase II-directed cytotoxic drugs.
Oncology research 1993;5(3):133-8.
1993: Haldane A; Holdaway K M; Finlay G J; Baguley B C
Cytokinetic differences in the action of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin.
Cancer chemotherapy and pharmacology 1993;32(6):463-70.
1993: Marshall E S; Holdaway K M; Shaw J H; Finlay G J; Matthews J H; Baguley B C
Anticancer drug sensitivity profiles of new and established melanoma cell lines.
Oncology research 1993;5(8):301-9.
1992: Thomsen L L; Baguley B C; Rustin G J; O'Reilly S M
Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma. II: Induction of nitric oxide production.
British journal of cancer 1992;66(4):723-7.
1992: Gamage S A; Rewcastle G W; Atwell G J; Baguley B C; Denny W A
Structure-activity relationships for substituted 9-oxo-9,10-dihydroacridine-4-acetic acids: analogues of the colon tumour active agent xanthenone-4-acetic acid.
Anti-cancer drug design 1992;7(5):403-14.
1992: Palmer B D; Wickham G; Craik D J; McFadyen W D; Wakelin L P; Baguley B C; Denny W A
Synthesis, DNA binding interactions and biological activity of bis platinum (II) complexes of N,N,N',N'-tetrakis(2-aminoethyl)diamines.
Anti-cancer drug design 1992;7(5):385-401.
1992: Lee H H; Palmer B D; Baguley B C; Chin M; McFadyen W D; Wickham G; Thorsbourne-Palmer D; Wakelin L P; Denny W A
DNA-directed alkylating agents. 5. Acridinecarboxamide derivatives of (1,2-diaminoethane)dichloroplatinum(II).
Journal of medicinal chemistry 1992;35(16):2983-7.
1992: Ching L M; Joseph W R; Baguley B C
Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice.
British journal of cancer 1992;66(1):128-30.
1992: Ching L M; Joseph W R; Baguley B C
Stimulation of macrophage tumouricidal activity by 5,6-dimethyl-xanthenone-4-acetic acid, a potent analogue of the antitumour agent flavone-8-acetic acid.
Biochemical pharmacology 1992;44(1):192-5.
1992: Iwamoto Y; Ferguson L R; Pearson A; Baguley B C
Photo-enhancement of the mutagenicity of 9-anilinoacridine derivatives related to the antitumour agent amsacrine.
Mutation research 1992;268(1):35-41.
1992: Thomsen L L; Ching L M; Joseph W R; Baguley B C; Gavin J B
Nitric oxide production in endotoxin-resistant C3H/HeJ mice stimulated with flavone-8-acetic acid and xanthenone-4-acetic acid analogues.
Biochemical pharmacology 1992;43(11):2401-6.
1992: Marshall E S; Finlay G J; Matthews J H; Shaw J H; Nixon J; Baguley B C
Microculture-based chemosensitivity testing: a feasibility study comparing freshly explanted human melanoma cells with human melanoma cell lines.
Journal of the National Cancer Institute 1992;84(5):340-5.
1992: Thomsen L L; Baguley B C; Ching L M; Gavin J B
Modulation of superoxide production from murine macrophages by the antitumour agent flavone acetic acid and xanthenone acetic acid analogues.
Biochemical pharmacology 1992;43(2):386-9.
1992: Lee H H; Palmer B D; Boyd M; Baguley B C; Denny W A
Potential antitumor agents. 64. Synthesis and antitumor evaluation of dibenzo[1,4]dioxin-1-carboxamides: a new class of weakly binding DNA-intercalating agents.
Journal of medicinal chemistry 1992;35(2):258-66.
1992: Haldane A; Finlay G J; Gavin J B; Baguley B C
Unusual dynamics of killing of cultured Lewis lung cells by the DNA-intercalating antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
Cancer chemotherapy and pharmacology 1992;29(6):475-9.
1992: Holdaway K M; Finlay G J; Baguley B C
Relationship of cell cycle parameters to in vitro and in vivo chemosensitivity for a series of Lewis lung carcinoma lines.
European journal of cancer (Oxford, England : 1990) 1992;28A(8-9):1427-31.
1992: Zwi L J; Baguley B C; Gavin J B; Holdaway K M; Wilson W R
The role of immune effector cells in flavone acetic acid-induced injury to tumor cells in EMT6 spheroids.
Oncology research 1992;4(8-9):333-9.
1992: Thomsen L L; Baguley B C; Wilson W R
Nitric oxide: its production in host-cell-infiltrated EMT6 spheroids and its role in tumour cell killing by flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid.
Cancer chemotherapy and pharmacology 1992;31(2):151-5.
1992: Baguley B C; Finlay G J; Ching L M
Resistance mechanisms to topoisomerase poisons: the application of cell culture methods.
Oncology research 1992;4(7):267-74.
1991: Ferguson L R; Turner P M; Baguley B C
Stimulation of bacterial mutagenicity by inhibitors of mammalian cell multidrug resistance.
Mutation research 1991;264(4):231-4.
1991: Baguley B C
Topoisomerases and cancer treatment.
The New Zealand medical journal 1991;104(924):491-3.
1991: Rewcastle G W; Atwell G J; Baguley B C; Boyd M; Thomsen L L; Zhuang L; Denny W A
Potential antitumor agents. 63. Structure-activity relationships for side-chain analogues of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid.
Journal of medicinal chemistry 1991;34(9):2864-70.
1991: Gravatt G L; Baguley B C; Wilson W R; Denny W A
DNA-directed alkylating agents. 4. 4-anilinoquinoline-based minor groove directed aniline mustards.
Journal of medicinal chemistry 1991;34(5):1552-60.
1991: Kestell P; McKeage M J; Baguley B C
Determination of xanthenone-4-acetic acid in mouse plasma by high-performance liquid chromatography.
Journal of chromatography 1991;564(1):315-21.
1991: Baguley B C
DNA intercalating anti-tumour agents.
Anti-cancer drug design 1991;6(1):1-35.
1991: Rewcastle G W; Atwell G J; Palmer B D; Boyd P D; Baguley B C; Denny W A
Potential antitumor agents. 62. Structure-activity relationships for tricyclic compounds related to the colon tumor active drug 9-oxo-9H-xanthene-4-acetic acid.
Journal of medicinal chemistry 1991;34(2):491-6.
1991: Rewcastle G W; Atwell G J; Li Z A; Baguley B C; Denny W A
Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids.
Journal of medicinal chemistry 1991;34(1):217-22.
1991: Thomsen L L; Ching L M; Zhuang L; Gavin J B; Baguley B C
Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice.
Cancer research 1991;51(1):77-81.
1991: Ching L M; McKeage M J; Joseph W R; Kestell P; Zwi L J; Baguley B C
Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-dimethyl-xanthenone-4-acetic acid [correction of 5,6-methyl-] and flavone acetic acid.
Cancer chemotherapy and pharmacology 1991;28(6):414-9.
1991: McKeage M J; Kestell P; Denny W A; Baguley B C
Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice.
Cancer chemotherapy and pharmacology 1991;28(6):409-13.
1991: Baguley B C; Holdaway K M; Thomsen L L; Zhuang L; Zwi L J
Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism.
European journal of cancer (Oxford, England : 1990) 1991;27(4):482-7.
1991: Ching L M; Joseph W R; Zhuang L; Atwell G J; Rewcastle G W; Denny W A; Baguley B C
Induction of natural killer activity by xanthenone analogues of flavone acetic acid: relation with antitumour activity.
European journal of cancer (Oxford, England : 1990) 1991;27(1):79-83.
1991: Ching L M; Finlay G J; Joseph W R; Baguley B C
In vitro methods for screening agents with an indirect mechanism of antitumour activity: xanthenone analogues of flavone acetic acid.
European journal of cancer (Oxford, England : 1990) 1991;27(12):1684-9.
1991: Harvey V J; Hardy J R; Smith S; Grove W; Baguley B C
Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 1991;27(12):1617-20.
1990: Zwi L J; Baguley B C; Gavin J B; Wilson W R
Necrosis in non-tumour tissues caused by flavone acetic acid and 5,6-dimethyl xanthenone acetic acid.
British journal of cancer 1990;62(6):932-4.
1990: Valu K K; Gourdie T A; Boritzki T J; Gravatt G L; Baguley B C; Wilson W R; Wakelin L P; Woodgate P D; Denny W A
DNA-directed alkylating agents. 3. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the length of the linker chain.
Journal of medicinal chemistry 1990;33(11):3014-9.
1990: Palmer B D; Lee H H; Johnson P; Baguley B C; Wickham G; Wakelin L P; McFadyen W D; Denny W A
DNA-directed alkylating agents. 2. Synthesis and biological activity of platinum complexes linked to 9-anilinoacridine.
Journal of medicinal chemistry 1990;33(11):3008-14.
1990: Thomsen L L; Ching L M; Baguley B C
Evidence for the production of nitric oxide by activated macrophages treated with the antitumor agents flavone-8-acetic acid and xanthenone-4-acetic acid.
Cancer research 1990;50(21):6966-70.
1990: Zwi L J; Baguley B C; Gavin J B; Wilson W R
The use of vascularised spheroids to investigate the action of flavone acetic acid on tumour blood vessels.
British journal of cancer 1990;62(2):231-7.
1990: Atwell G J; Rewcastle G W; Baguley B C; Denny W A
Potential antitumor agents. 60. Relationships between structure and in vivo colon 38 activity for 5-substituted 9-oxoxanthene-4-acetic acids.
Journal of medicinal chemistry 1990;33(5):1375-9.
1990: Gourdie T A; Valu K K; Gravatt G L; Boritzki T J; Baguley B C; Wakelin L P; Wilson W R; Woodgate P D; Denny W A
DNA-directed alkylating agents. 1. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the reactivity of the mustard.
Journal of medicinal chemistry 1990;33(4):1177-86.
1990: Baguley B C
The possible role of electron-transfer complexes in the antitumour action of amsacrine analogues.
Biophysical chemistry 1990;35(2-3):203-12.
1990: Finlay G J; Baguley B C; Snow K; Judd W
Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues.
Journal of the National Cancer Institute 1990;82(8):662-7.
1990: Rewcastle G W; Kestell P; Baguley B C; Denny W A
Light-induced breakdown of flavone acetic acid and xanthenone analogues in solution.
Journal of the National Cancer Institute 1990;82(6):528-9.
1990: Baguley B C; Holdaway K M; Fray L M
Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance.
Journal of the National Cancer Institute 1990;82(5):398-402.
1990: Kestell P; Paxton J W; Evans P C; Young D; Jurlina J L; Robertson I G; Baguley B C
Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice.
Cancer research 1990;50(3):503-8.
1990: Denny W A; Rewcastle G W; Baguley B C
Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of "minimal" DNA-intercalating agents which may not act via topoisomerase II.
Journal of medicinal chemistry 1990;33(2):814-9.
1990: Baguley B C; Turner P M; Ferguson L R
Protection by inhibitors of multidrug resistance against mitochondrial mutagenesis in Saccharomyces cerevisiae.
European journal of cancer (Oxford, England : 1990) 1990;26(1):55-60.
1990: Ching L M; Finlay G J; Joseph W R; Baguley B C
Comparison of the cytotoxicity of amsacrine and its analogue CI-921 against cultured human and mouse bone marrow tumour cells.
European journal of cancer (Oxford, England : 1990) 1990;26(1):49-54.
1990: Ferguson L R; Hill C M; Baguley B C
Genetic toxicology of tricyclic carboxamides, a new class of DNA binding antitumour agent.
European journal of cancer (Oxford, England : 1990) 1990;26(6):709-14.
1990: Finlay G J; Baguley B C
Potentiation by phenylbisbenzimidazoles of cytotoxicity of anticancer drugs directed against topoisomerase II.
European journal of cancer (Oxford, England : 1990) 1990;26(5):586-9.
1989: Finlay G J; Wilson W R; Baguley B C
Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs.
European journal of cancer & clinical oncology 1989;25(12):1695-701.
1989: Ching L M; Baguley B C
Hyporesponsiveness of macrophages from C3H/HeJ (endotoxin-resistant) mice to the antitumour agent flavone acetic acid (NSC 347512).
European journal of cancer & clinical oncology 1989;25(10):1513-5.
1989: Liley D T; Wiggins P M; Baguley B C
Localization of a nonintercalative DNA binding antitumour drug in mitochondria: relationship to multidrug resistance.
European journal of cancer & clinical oncology 1989;25(9):1287-93.
1989: Atwell G J; Rewcastle G W; Baguley B C; Denny W A
Synthesis and anti-tumour activity of topologically-related analogues of flavoneacetic acid.
Anti-cancer drug design 1989;4(2):161-9.
1989: Zwi L J; Baguley B C; Gavin J B; Wilson W R
Blood flow failure as a major determinant in the antitumor action of flavone acetic acid.
Journal of the National Cancer Institute 1989;81(13):1005-13.
1989: Ching L M; Baguley B C
Reduction of cytotoxic effector cell activity in colon 38 tumours following treatment with flavone acetic acid.
European journal of cancer & clinical oncology 1989;25(7):1061-5.
1989: Ching L M; Baguley B C
Effect of flavone acetic acid (NSC 347,512) on splenic cytotoxic effector cells and their role in tumour necrosis.
European journal of cancer & clinical oncology 1989;25(5):821-8.
1989: Rewcastle G W; Atwell G J; Baguley B C; Calveley S B; Denny W A
Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo.
Journal of medicinal chemistry 1989;32(4):793-9.
1989: Atwell G J; Baguley B C; Denny W A
Potential antitumor agents. 57. 2-Phenylquinoline-8-carboxamides as "minimal" DNA-intercalating antitumor agents with in vivo solid tumor activity.
Journal of medicinal chemistry 1989;32(2):396-401.
1989: Finlay G J; Baguley B C
Selectivity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro.
European journal of cancer & clinical oncology 1989;25(2):271-7.
1989: Baguley B C; Calveley S B; Crowe K K; Fray L M; O'Rourke S A; Smith G P
Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on colon 38 tumours in mice.
European journal of cancer & clinical oncology 1989;25(2):263-9.
1989: Ferguson L R; van Zijl P; Baguley B C
Mutagenicity profiles of newer amsacrine analogues with activity against solid tumours: comparison of microbial and mammalian systems.
European journal of cancer & clinical oncology 1989;25(2):255-61.
1988: Hardy J R; Harvey V J; Paxton J W; Evans P; Smith S; Grove W; Grillo-Lopez A J; Baguley B C
Phase I trial of the amsacrine analogue 9-[( 2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921).
Cancer research 1988;48(22):6593-6.
1988: Schneider E; Darkin S J; Lawson P A; Ching L M; Ralph R K; Baguley B C
Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II.
European journal of cancer & clinical oncology 1988;24(11):1783-90.
1988: Baguley B C
The potential of molecular and cellular biology.
The New Zealand medical journal 1988;101(856 Pt 2):700-2.
1988: Ching L M; Baguley B C
Enhancement of in vitro cytotoxicity of mouse peritoneal exudate cells by flavone acetic acid (NSC 347512).
European journal of cancer & clinical oncology 1988;24(9):1521-5.
1988: Ferguson L R; Baguley B C
Verapamil as a co-mutagen in the Salmonella/mammalian microsome mutagenicity test.
Mutation research 1988;209(1-2):57-62.
1988: Atwell G J; Bos C D; Baguley B C; Denny W A
Potential antitumor agents. 56. "Minimal" DNA-intercalating ligands as antitumor drugs: phenylquinoline-8-carboxamides.
Journal of medicinal chemistry 1988;31(5):1048-52.
1988: Finlay G J; Smith G P; Fray L M; Baguley B C
Effect of flavone acetic acid on Lewis lung carcinoma: evidence for an indirect effect.
Journal of the National Cancer Institute 1988;80(4):241-5.
1988: Atwell G J; Baguley B C; Denny W A
Potential antitumor agents. 55. 6-Phenylphenanthridine-4-carboxamides: a new class of DNA-intercalating antitumor agents.
Journal of medicinal chemistry 1988;31(4):774-9.
1988: Palmer B D; Rewcastle G W; Atwell G J; Baguley B C; Denny W A
Potential antitumor agents. 54. Chromophore requirements for in vivo antitumor activity among the general class of linear tricyclic carboxamides.
Journal of medicinal chemistry 1988;31(4):707-12.
1988: Baguley B C; Finlay G J
Derivatives of amsacrine: determinants required for high activity against Lewis lung carcinoma.
Journal of the National Cancer Institute 1988;80(3):195-9.
1988: Baguley B C; Calveley S B; Harvey V J
Effects of CI-921, an analogue of amsacrine, on advanced Lewis lung tumours in mice: relevance to clinical trials.
European journal of cancer & clinical oncology 1988;24(2):211-8.
1988: Baguley B C; Finlay G J
Relationship between the structure of analogues of amsacrine and their degree of cross-resistance to adriamycin-resistant P388 leukaemia cells.
European journal of cancer & clinical oncology 1988;24(2):205-10.
1988: Ferguson L R; van Zijl P; Baguley B C
Comparison of the mutagenicity of amsacrine with that of a new clinical analogue, CI-921.
Mutation research 1988;204(2):207-17.
1988: Robbie M A; Baguley B C; Denny W A; Gavin J B; Wilson W R
Mechanism of resistance of noncycling mammalian cells to 4'-(9-acridinylamino)methanesulfon-m-anisidide: comparison of uptake, metabolism, and DNA breakage in log- and plateau-phase Chinese hamster fibroblast cell cultures.
Cancer research 1988;48(2):310-9.
1988: Paxton J W; Hardy J R; Evans P C; Harvey V J; Baguley B C
The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4 -acridinecarboxamide (CI-921) in a phase 1 trial.
Cancer chemotherapy and pharmacology 1988;22(3):235-40.
1988: Kestell P; Paxton J W; Robertson I G; Evans P C; Dormer R A; Baguley B C
Thiolytic cleavage and binding of the antitumour agent CI-921 in blood.
Drug metabolism and drug interactions 1988;6(3-4):327-36.
1988: Robertson I G; Atwell G J; Baguley B C
The relationship between lipophilic-hydrophilic balance, uptake and anti-bacteriophage lambda activity of experimental anti-tumour bisquaternary salts.
Chemico-biological interactions 1988;65(1):85-95.
1987: Denny W A; Atwell G J; Baguley B C
'Minimal' DNA-intercalating agents as anti-tumour drugs: 2-styrylquinoline analogues of amsacrine.
Anti-cancer drug design 1987;2(3):263-70.
1987: Finlay G J; Wilson W R; Baguley B C
Cytokinetic factors in drug resistance of Lewis lung carcinoma: comparison of cells freshly isolated from tumours with cells from exponential and plateau-phase cultures.
British journal of cancer 1987;56(6):755-62.
1987: Denny W A; Baguley B C
Amsacrine analogues with extended chromophores: DNA binding and anti-tumour activity.
Anti-cancer drug design 1987;2(1):61-70.
1987: Ching L M; Baguley B C
Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347 512).
European journal of cancer & clinical oncology 1987;23(7):1047-50.
1987: Baguley B C; Wilson W R
Comparison of in vivo and in vitro drug sensitivities of Lewis lung carcinoma and P388 leukaemia to analogues of amsacrine.
European journal of cancer & clinical oncology 1987;23(6):607-13.
1986: Rewcastle G W; Denny W A; Wilson W R; Baguley B C
In vitro and in vivo assessment of activity of new anilino-substituted analogues of amsacrine against Lewis lung carcinoma.
Anti-cancer drug design 1986;1(3):215-22.
1986: Denny W A; Twigden S J; Baguley B C
Steric constraints for DNA binding and biological activity in the amsacrine series.
Anti-cancer drug design 1986;1(2):125-32.

Sign-in to see more